Prevalence of post-vaccine side effects among COVID-19 immunized community of Southern Pakistan

PLoS One. 2023 May 23;18(5):e0285736. doi: 10.1371/journal.pone.0285736. eCollection 2023.

Abstract

Background: The response to the vaccine may vary among individuals. Hence, it is important to know how often individuals experience side effects after immunization against COVID-19.

Objective: This study aimed to assess the incidence of side effects following COVID-19 vaccination across different vaccine recipients in Southern Pakistan and identify the potential factors associated with these side effects in the population.

Methods: The survey was conducted across Pakistan through Google-forms Links from August to October 2021. The questionnaire included demographic information and COVID-19 vaccine information. Chi-square (x2) was performed for comparative analysis to check the significance level with P <0.05. The final analysis included 507 participants who had received COVID-19 vaccines.

Results: Of the total 507 COVID-19 vaccines recipients, 24.9% received CoronaVac, 36.5% received BBIBP-CorV, 14.2% received BNT162b2, 13.8% received AZD1222, and 10.7% received mRNA-1273. The most prominent side effects after the first dose were fever, weakness, lethargy, and pain at the site of injection. Moreover, the most commonly reported side effects after the second dose were pain at the injection site, headache, body ache, lethargy, fever, chills, flu-like symptoms, and diarrhea.

Conclusion: Our results suggested that the side effects due to COVID-19 vaccination can vary between the first and second doses and type of COVID-19 vaccine. Our findings suggest continuing monitoring of vaccine safety and the importance of individualized risk-benefit assessment for COVID-19 immunization.

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • ChAdOx1 nCoV-19
  • Drug-Related Side Effects and Adverse Reactions*
  • Fever
  • Humans
  • Lethargy
  • Pakistan
  • Prevalence
  • Vaccines*

Substances

  • sinovac COVID-19 vaccine
  • BIBP COVID-19 vaccine
  • COVID-19 Vaccines
  • BNT162 Vaccine
  • ChAdOx1 nCoV-19
  • Vaccines

Grants and funding

The authors received no specific funding for this work.